An investigational drug improved median survival while reducing risk of disease progression or death in persons with metastatic gastric cancer participating in the phase III REGARD trial.
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
Hybrid compounds formed from structural features of the antinausea agent thalidomide and curcumin destroyed multiple myeloma cells in recent lab experiments.
A newly discovered weakness in cancer cells may make them more susceptible to chemotherapy and other treatments.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
A new way of analyzing data acquired in magnetic resonance imaging appears to identify whether or not tumors are responding to anti-angiogenesis therapy.
After 18 years of follow-up, the drug finasteride was shown to reduce the risk for prostate cancer by approximately one third, but did not significantly affect overall survival in men or survival after prostate cancer diagnosis.
The FDA granted marketing approval to an orphan drug for the topical treatment of stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma (CTCL).
Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome. The proteasome is the cellular structure that disposes the waste of the cell by breaking down damaged or unneeded proteins
The drug pomalidomide, already approved for use in persons with multiple myeloma, is a promising therapeutic agent for central nervous system (CNS) lymphoma, say investigators.
Researchers are suggesting that high-dose interleukin-2 (HD IL-2) therapy should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy, based on the encouraging results of a small retrospective review.
Radium-223 dichloride (Xofigo) significantly improved overall survival and caused few adverse events in men with castration-resistant prostate cancer (CRPC) that had metastasized to bone, researchers reported.
Lenalidomide plus dexamethasone delays progression, improves survival versus observation
Treatment combining arsenic trioxide with standard care for APL was just as effective as conventional therapy in low-to-intermediate risk disease.
The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.
FDA-related news items of relevance from the month of June, 2013.
The drug targets interactions with the tumor microenvironment and promotes remission in patients with relapsed chronic lymphocytic leukemia, according to a study in the New England Journal of Medicine.
The AUA developed its new clinical guideline on castration-resistant prostate cancer by creating six index patients to represent the most common clinical scenarios encountered when managing the disease.
Michael L. Wang, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a phase 2 study to examine use of oral ibrutinib in patients with relapsed or refractory mantle-cell lymphoma.
Researchers at The University of Texas Southwestern Medical Center in Dallas, Texas, have developed a class of drugs known as peptidomimetics, which disrupt androgen receptor activity in a unique way.
A subset of lung cancers are caused by mutations in the gene NTRK1, according to research presented at the annual meeting of the American Society of Clinical Oncology.
Oncology drug shortages have been faced by 83% of oncologists. These shortages delay treatments, force rationing and expensive drug substitutions, and slow clinical trial enrollment.
The first clinical trial of the monoclonal antibody lambrolizumab for persons with advanced melanoma demonstrated that even the lowest dose resulted in a high rate of sustained tumor regression, with only mild side effects for the patient.
FDA-related news items of relevance from the month of May, 2013.
A longstanding mystery about how pancreatic tumor cells sustain themselves has been unraveled by a new study. This opens up new therapeutic possibilities for a notorious lethal disease with few treatment options.
Gossypol plus navitoclax may be effective in destroying resistant chronic lymphocytic leukemia (CLL) cells in the lymph nodes and bone marrow.
What are the new Medicare guidelines for the administration of an epoetin alfa injection (Procrit) or a darbepoetin alfa injection (Aranesp)?
Breast cancer has variability from the different cell types with different patterns of gene expression in breast cancer, but a new study found that that variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients. These findings were presented at the 5th IMPAKT Breast Cancer Conference.
A new class of drugs targeting the genetic material of skin cancer has been successfully tested in humans for the first time. This opens the way to new treatments for a range of conditions from skin cancers to eye diseases.
A new retrospective study suggests that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer who harbor specific mutations in the HER2 protein.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|